AAPL322.63+7.29 (+2.31%) ▲|ABBV252.17+1.26 (+0.50%) ▲|ABT104.35-0.88 (-0.84%) ▼|ACN178.53+2.73 (+1.55%) ▲|ADBE251.73-3.13 (-1.23%) ▼|AMAT458.68-10.18 (-2.17%) ▼|AMD507.81-13.29 (-2.55%) ▼|AMGN383.61-7.66 (-1.96%) ▼|AMT173.00-2.44 (-1.39%) ▼|AMZN252.55+0.15 (+0.06%) ▲|AVGO364.08-0.30 (-0.08%) ▼|AXP321.38-0.42 (-0.13%) ▼|BA207.42+1.00 (+0.48%) ▲|BAC62.47-0.20 (-0.32%) ▼|BKNG176.11+2.68 (+1.54%) ▲|BLK1,073.53+1.50 (+0.14%) ▲|BMY64.03-0.38 (-0.59%) ▼|BNY163.10+0.59 (+0.36%) ▲|BRK-B505.82-0.91 (-0.18%) ▼|C138.16+0.36 (+0.26%) ▲|CAT806.74-8.83 (-1.08%) ▼|CL88.03+0.00 (+0.00%) ▲|CMCSA24.92+0.33 (+1.32%) ▲|COF208.53-2.33 (-1.11%) ▼|COP136.38-0.15 (-0.11%) ▼|COST902.78+0.18 (+0.02%) ▲|CRM245.57+1.41 (+0.58%) ▲|CSCO108.99-0.44 (-0.40%) ▼|CVS95.35-0.03 (-0.03%) ▼|CVX213.24-0.57 (-0.27%) ▼|DE677.60+0.39 (+0.06%) ▲|DHR202.23-2.63 (-1.28%) ▼|DIS104.86+0.68 (+0.65%) ▲|DUK119.41-1.02 (-0.85%) ▼|EMR148.62-1.73 (-1.15%) ▼|FDX312.28+3.09 (+1.00%) ▲|GD353.47+0.80 (+0.23%) ▲|GE325.22-0.20 (-0.06%) ▼|GEV934.42-16.62 (-1.75%) ▼|GILD144.40-1.25 (-0.86%) ▼|GM85.13+1.37 (+1.64%) ▲|GOOG327.56-0.82 (-0.25%) ▼|GOOGL329.97-0.68 (-0.21%) ▼|GS1,025.33-3.45 (-0.34%) ▼|HD307.15-3.30 (-1.06%) ▼|HON203.59-1.34 (-0.65%) ▼|IBM238.05-1.90 (-0.79%) ▼|INTC101.57-4.67 (-4.40%) ▼|INTU315.51+1.57 (+0.50%) ▲|ISRG359.90+6.66 (+1.88%) ▲|JNJ266.69-0.39 (-0.15%) ▼|JPM353.78-0.93 (-0.26%) ▼|KO88.40+0.85 (+0.97%) ▲|LIN461.80-4.86 (-1.04%) ▼|LLY1,128.18+3.97 (+0.35%) ▲|LMT527.14+2.68 (+0.51%) ▲|LOW196.10-2.50 (-1.26%) ▼|LRCX304.33-11.51 (-3.64%) ▼|MA565.40-2.10 (-0.37%) ▼|MCD253.33-0.15 (-0.06%) ▼|MDLZ61.99-0.43 (-0.69%) ▼|MDT91.62-0.28 (-0.30%) ▼|META651.46-2.24 (-0.34%) ▼|MMM162.11-2.30 (-1.40%) ▼|MO68.79+0.90 (+1.33%) ▲|MRK144.82-2.71 (-1.84%) ▼|MS215.00-0.35 (-0.16%) ▼|MSFT492.59+0.94 (+0.19%) ▲|MU983.74-44.03 (-4.28%) ▼|NEE82.37-0.28 (-0.34%) ▼|NFLX75.97-0.06 (-0.08%) ▼|NKE37.10-0.26 (-0.68%) ▼|NOW134.00+2.89 (+2.20%) ▲|NVDA218.44-5.23 (-2.34%) ▼|ORCL158.89-2.74 (-1.70%) ▼|PEP136.80+0.11 (+0.08%) ▲|PFE27.52-0.26 (-0.94%) ▼|PG142.30-0.34 (-0.24%) ▼|PLTR167.75-1.78 (-1.05%) ▼|PM190.44+4.73 (+2.54%) ▲|QCOM177.91+1.51 (+0.85%) ▲|RTX197.18-0.37 (-0.19%) ▼|SBUX99.98-0.06 (-0.06%) ▼|SCHW107.01+0.47 (+0.44%) ▲|SO87.87-0.47 (-0.53%) ▼|SPG205.70+1.17 (+0.57%) ▲|T25.49+0.34 (+1.33%) ▲|TMO601.57-4.12 (-0.68%) ▼|TMUS176.58-0.76 (-0.43%) ▼|TSLA366.86-0.95 (-0.26%) ▼|TXN260.50-1.09 (-0.42%) ▼|UBER70.98-0.10 (-0.14%) ▼|UNH391.11-1.95 (-0.50%) ▼|UNP285.51+0.77 (+0.27%) ▲|UPS99.80+0.58 (+0.58%) ▲|USB62.06-0.05 (-0.08%) ▼|V366.73-0.66 (-0.18%) ▼|VZ49.93+0.19 (+0.37%) ▲|WFC89.22-0.46 (-0.51%) ▼|WMT105.92+0.09 (+0.08%) ▲|XOM164.76+0.53 (+0.32%) ▲|AAPL322.63+7.29 (+2.31%) ▲|ABBV252.17+1.26 (+0.50%) ▲|ABT104.35-0.88 (-0.84%) ▼|ACN178.53+2.73 (+1.55%) ▲|ADBE251.73-3.13 (-1.23%) ▼|AMAT458.68-10.18 (-2.17%) ▼|AMD507.81-13.29 (-2.55%) ▼|AMGN383.61-7.66 (-1.96%) ▼|AMT173.00-2.44 (-1.39%) ▼|AMZN252.55+0.15 (+0.06%) ▲|AVGO364.08-0.30 (-0.08%) ▼|AXP321.38-0.42 (-0.13%) ▼|BA207.42+1.00 (+0.48%) ▲|BAC62.47-0.20 (-0.32%) ▼|BKNG176.11+2.68 (+1.54%) ▲|BLK1,073.53+1.50 (+0.14%) ▲|BMY64.03-0.38 (-0.59%) ▼|BNY163.10+0.59 (+0.36%) ▲|BRK-B505.82-0.91 (-0.18%) ▼|C138.16+0.36 (+0.26%) ▲|CAT806.74-8.83 (-1.08%) ▼|CL88.03+0.00 (+0.00%) ▲|CMCSA24.92+0.33 (+1.32%) ▲|COF208.53-2.33 (-1.11%) ▼|COP136.38-0.15 (-0.11%) ▼|COST902.78+0.18 (+0.02%) ▲|CRM245.57+1.41 (+0.58%) ▲|CSCO108.99-0.44 (-0.40%) ▼|CVS95.35-0.03 (-0.03%) ▼|CVX213.24-0.57 (-0.27%) ▼|DE677.60+0.39 (+0.06%) ▲|DHR202.23-2.63 (-1.28%) ▼|DIS104.86+0.68 (+0.65%) ▲|DUK119.41-1.02 (-0.85%) ▼|EMR148.62-1.73 (-1.15%) ▼|FDX312.28+3.09 (+1.00%) ▲|GD353.47+0.80 (+0.23%) ▲|GE325.22-0.20 (-0.06%) ▼|GEV934.42-16.62 (-1.75%) ▼|GILD144.40-1.25 (-0.86%) ▼|GM85.13+1.37 (+1.64%) ▲|GOOG327.56-0.82 (-0.25%) ▼|GOOGL329.97-0.68 (-0.21%) ▼|GS1,025.33-3.45 (-0.34%) ▼|HD307.15-3.30 (-1.06%) ▼|HON203.59-1.34 (-0.65%) ▼|IBM238.05-1.90 (-0.79%) ▼|INTC101.57-4.67 (-4.40%) ▼|INTU315.51+1.57 (+0.50%) ▲|ISRG359.90+6.66 (+1.88%) ▲|JNJ266.69-0.39 (-0.15%) ▼|JPM353.78-0.93 (-0.26%) ▼|KO88.40+0.85 (+0.97%) ▲|LIN461.80-4.86 (-1.04%) ▼|LLY1,128.18+3.97 (+0.35%) ▲|LMT527.14+2.68 (+0.51%) ▲|LOW196.10-2.50 (-1.26%) ▼|LRCX304.33-11.51 (-3.64%) ▼|MA565.40-2.10 (-0.37%) ▼|MCD253.33-0.15 (-0.06%) ▼|MDLZ61.99-0.43 (-0.69%) ▼|MDT91.62-0.28 (-0.30%) ▼|META651.46-2.24 (-0.34%) ▼|MMM162.11-2.30 (-1.40%) ▼|MO68.79+0.90 (+1.33%) ▲|MRK144.82-2.71 (-1.84%) ▼|MS215.00-0.35 (-0.16%) ▼|MSFT492.59+0.94 (+0.19%) ▲|MU983.74-44.03 (-4.28%) ▼|NEE82.37-0.28 (-0.34%) ▼|NFLX75.97-0.06 (-0.08%) ▼|NKE37.10-0.26 (-0.68%) ▼|NOW134.00+2.89 (+2.20%) ▲|NVDA218.44-5.23 (-2.34%) ▼|ORCL158.89-2.74 (-1.70%) ▼|PEP136.80+0.11 (+0.08%) ▲|PFE27.52-0.26 (-0.94%) ▼|PG142.30-0.34 (-0.24%) ▼|PLTR167.75-1.78 (-1.05%) ▼|PM190.44+4.73 (+2.54%) ▲|QCOM177.91+1.51 (+0.85%) ▲|RTX197.18-0.37 (-0.19%) ▼|SBUX99.98-0.06 (-0.06%) ▼|SCHW107.01+0.47 (+0.44%) ▲|SO87.87-0.47 (-0.53%) ▼|SPG205.70+1.17 (+0.57%) ▲|T25.49+0.34 (+1.33%) ▲|TMO601.57-4.12 (-0.68%) ▼|TMUS176.58-0.76 (-0.43%) ▼|TSLA366.86-0.95 (-0.26%) ▼|TXN260.50-1.09 (-0.42%) ▼|UBER70.98-0.10 (-0.14%) ▼|UNH391.11-1.95 (-0.50%) ▼|UNP285.51+0.77 (+0.27%) ▲|UPS99.80+0.58 (+0.58%) ▲|USB62.06-0.05 (-0.08%) ▼|V366.73-0.66 (-0.18%) ▼|VZ49.93+0.19 (+0.37%) ▲|WFC89.22-0.46 (-0.51%) ▼|WMT105.92+0.09 (+0.08%) ▲|XOM164.76+0.53 (+0.32%) ▲|

27.5 C

New York

Thursday, September 10, 2026

/C O R R E C T I O N — Partillion Bioscience/

Holdun Family Office (Bahamas) Limited Confirms the Conclusion of its Licensed Wealth Management Business

Drivvr AI Welcomes Automotive Marketing Veteran Brian Voss as National Sales Director

Tag: investor

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels. Building on Celldex’s leadership in mast cell science, the data also demonstrated that neutralizing soluble stem cell factor (SCF) enables the potential for meaningful mast cell inhibition and depletion without impacting other KIT-dependent functions. CDX-622 is currently being studied in a Phase 1b proof of mechanism study in mild to moderate asthma to assess the impact of dual neutralization of SCF and TSLP.

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).